In this video, health-care analyst David Williamson walks investors through today's Aveo Pharmaceuticals (AVEO) bloodbath. Shares are down 50% as an FDA advisory committee voted overwhelmingly against its drug candidate tivozanib. Find out why the decision shook out like it did, and if Aveo is a bad news buy after today's extreme plunge.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Shares plunge 50% as Aveo Pharmaceutical's kidney cancer drug gets a 13-1 "no" vote.
David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Pfizer
PFE
$23.97
(0.38%)
$0.09
AVEO Pharmaceuticals
AVEO
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.